GSK to license Elsie’s oligonucleotide discovery platform

2024-02-15

引进/卖出寡核苷酸临床研究快速通道

GSK to license Elsie’s oligonucleotide discovery platform

Preview

来源: Pharmaceutical Technology

GSK’s option for a licence allows for the application of Elsie’s discovery platform and chemistry technologies in oligonucleotide drug discovery projects. Credit: Gorodenkoff / Shutterstock.com.

Preview

来源: Pharmaceutical Technology

GSK has exercised its option for a non-exclusive licence to Elsie Biotechnologies’s discovery platform to detect and develop new oligonucleotides.

The move follows a successful research collaboration initiated last year, aimed at harnessing the platform’s capabilities for oligonucleotide drug discovery.

In July 2023, GSK and Elsie Biotechnologies entered a research collaboration. Their goal was to advance the discovery and development of new oligonucleotides, prioritising efficacy, safety and delivery.

The partnership leveraged GSK’s expertise in deoxyribonucleic acid (DNA)-encoded library technologies and Elsie’s drug discovery platform.

During the initial research period, the companies focused on exploring the full potential of Elsie’s platform.

See Also:BMS signs $674m GenAI drug discovery deal with VantAI

Preview

来源: Pharmaceutical Technology

FDA grants fast track status to GSK’s bepirovirsen for hepatitis B

Preview

来源: Pharmaceutical Technology

GSK’s option for a non-exclusive licence was part of the original agreement, allowing for the application of Elsie’s discovery platform and chemistry technologies in GSK’s oligonucleotide drug discovery projects.

Elsie is entitled to receive a licence payment from GSK, along with future milestone payments on meeting development and commercial goals on a target-by-target basis.

Elsie Biotechnologies chief operating officer Kevin Green stated: “We are pleased that GSK has elected to license our platform technology following the research collaboration.

“GSK is a great innovator in the field of oligonucleotide therapeutics, and this licence validates the potential of our discovery platform, which we believe can power next-generation RNA medicines, optimised for safety, activity and delivery.”

Elsie has an ultra-high throughput process within its discovery platform. This system enables a comprehensive assessment of the oligonucleotide chemical space.

The company’s encoding technology also allows for the analysis of potential sequences and chemical modification patterns, enhancing activity, minimising toxicity and optimising the delivery of therapeutic candidates.

Elsie’s chemistry technologies offer a range of new reagents and processes. They are designed to synthesise varied oligonucleotide therapies with full synthetic control.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free WhitepaperCell and gene therapies: Pipe dream to pipeline

The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.

By Cytiva Thematic

Preview

来源: Pharmaceutical Technology

-->

By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构